NPs used in brain cancer treatment can be functionalized with specific ligands or antibodies that target tumor‐specific receptors, such as epidermal growth factor receptors (EGFR), which are commonly overexpressed in GBM. This evidence concerns the gene EGFR and glioblastoma.